CClinicalTrials.gg
RecruitingNCT06216756Updated Nov 25, 2025

Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee

An interventional study of osteochondral transplant on the femoral condyle in Osteochondral Defect, sponsored by AlloSource. Recruiting at 6 sites in United States. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by AlloSource · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
12 Years to 60 Years
Sex
All
01

Study summary

The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.

Read the detailed description

Patients between the ages of ≥12 years and ≤ 60 years who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 0.9-8.0 cm2 in size, and cystic changes requiring osseous repair, as confirmed by MRI , CT scan, or arthroscopy, and undergoing an osteochondral transplant procedure will be eligible for enrollment. Patients will receive one or more cryopreserved osteochondral allograft core transplants to replace damaged cartilage.

Patients will be followed for up to 60 months post-procedure (6 weeks, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months) to evaluate short and long-term outcomes of the procedure using the cryopreserved osteochondral allograft cores.

02

Conditions studied

  • Osteochondral Defect
03

In context

Lead sponsor

AlloSource is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients are ≥12 years and ≤ 60 years of age at the time of surgery.
  • Symptomatic patient presenting with moderate to severe pain in the index knee - unresponsive to conservative treatment (i.e., medication, bracing, physical therapy) and/or previous surgical intervention OR unsalvageable lesion that requires transplantation at the discretion of the treating physician.
  • Radiographically diagnosed, by MRI or CT scans, or through arthroscopy, to have a cartilage defect on the femoral condyle between 0.9-8.0 cm2 in size.
  • Will be having an osteochondral transplant procedure.
  • Has a mechanically stable knee or can be mechanically stabilized in the same procedure.
  • Has a normally aligned knee as confirmed by anatomic comparison to contralateral limb, or \<5° varus or valgus malalignment that has been corrected or will be corrected in same procedure.
  • Ipsilateral knee compartment has intact menisci or requires partial meniscectomy ≤ 50% resulting in stable menisci.
  • Confirmation MRI, CT scan, or arthroscopy obtained pre-operatively within 90 days of surgery
  • Willingness to follow standardized rehabilitation procedures.
  • Has the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Bipolar articular cartilage involvement (kissing lesions) of the ipsilateral compartment (i.e., > than ICRS Grade 2 on the opposing articular surface).
  • Has had a prior osteochondral allograft transplant procedure in the same knee.
  • Will be receiving a meniscus allograft transplantation in the same procedure.
  • Body Mass Index (BMI)of ≥ 35 kg/m2.
  • Active malignancy: undergoing treatment for tumor or boney traumatic injury or a history of any invasive malignancy (except non-melanoma skin cancer) unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.
  • Clinical and/or radiographic disease in the affected joint that includes generalized osteoarthritis, gout or a history of gout or pseudo-gout.
  • Active local microbial infection or a systemic infection, including HIV, syphilis, Hepatitis B or Hepatitis C.
  • Currently immunologically suppressed or immunocompromised, or a medical condition requiring radiation and/or chemotherapy.
  • Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer, or uncontrolled diabetes.
  • Has a history of any inflammatory joint arthropathy.
  • Currently using/chronic on oral corticosteroids.
  • Received interarticular corticosteroid injection ≤ 90 days prior to surgery.
  • Received hyaluronic acid injections into the joint space ≤ 45 days prior to surgery.
  • Is a female patient who is pregnant.
  • Physically or mentally compromised (i.e., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his/her ability to participate in the clinical study.
  • Has a history of substance abuse- (including but not limited to recreational drugs, alcohol) or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an in-patient substance abuse program.
  • Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol.
  • Is currently involved in a study of another investigational product for similar purpose or has been in the previous 90 days.
  • Has any contraindications for MRI.
  • Is having the procedure as part of a Worker's Compensation claim.
  • Is a ward of the state, prisoner, or transient.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Osteochondral transplant on the femoral condyle

    Eligible and enrolled patients will receive one or more cryopreserved osteochondral allograft core as part of their osteochondral transplant procedure

    Procedure: osteochondral transplant on the femoral condyle

Interventions

  • Procedureosteochondral transplant on the femoral condyle

    Patients between the ages of ≥12 years and ≤ 60 years who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 0.9-8.0 cm2 in size, and cystic changes requiring osseous repair, as confirmed by MRI , CT scan, or arthroscopy and will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.

06

What researchers measure

Primary outcomes

  1. International Knee Documentation Committee (IKDC) score

    Change of physical functioning and pain from baseline as assessed by the subjective International Knee Documentation Committee (IKDC) score. Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.

    Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months post procedure

Secondary outcomes

  1. Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Change from baseline (pre-operative) Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.

    Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  2. Assessment of repair cartilage structure

    Assessment of repair cartilage structure, using Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores, as measured by Magnetic Resonance Imaging (MRI). Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.

    Time frame: 12 months, 24 months and 60 months post procedure

  3. Graft incorporation

    Assessment of graft incorporation using Magnetic Resonance Imaging (MRI)

    Time frame: 12 months, 24 months and 60 months post procedure

  4. 12-item Veterans RAND (VR-12)

    Change from baseline (pre-operative) The instrument is primarily used to measure health related quality of life, to estimate disease burden and to evaluate disease-specific benchmarks with other populations. The 12 items are summarized into two scores, a "Physical Health Summary Measure" and a "Mental Health Summary Measure."

    Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months post procedure

  5. Revision surgery

    Incidences of revision surgeries during study follow up time period

    Time frame: 60 months post-procedure

07

Study locations

5 of 6 sites recruiting
  • Banner- University Medical Center- Phoenix Orthopedic and Sports Medicine Institute
    Phoenix, Arizona 85006, United States
    Recruiting
  • Cedars-Sinai Kerlan Jobe Institute
    Los Angeles, California 90045, United States
    Not yet recruiting
  • Stanford Medicine-Orthopaedics and Sports Medicine in Redwood City
    Redwood City, California 94063, United States
    Recruiting
  • University of California San Francisco
    San Francisco, California 94158, United States
    Recruiting
  • Rush Copley Medical Center
    Aurora, Illinois 60504, United States
    • Starlyn Nadeau, RN · Contact · starlyn_nadeau@rush.edu · 630-361-4267
    • Brian E Walczak, DO, PhD · Principal investigator
    Recruiting
  • University of Kentucky Research Foundation
    Lexington, Kentucky 40506, United States
    • Caitlin Conley · Contact · caitlin.conley2@uky.edu · 859-257-1939
    • Austin Stone, MD, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — After patients have signed the ICF and have been determined to meet the inclusion/exclusion criteria, the patient will be given a patient identification number that consists of a 2-digit site number and a 3-digit patient number. As allowed by governing privacy requirements, this will serve as a patient's identifier on all study-related documentation.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06216756
Lead sponsor
AlloSource
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Dec 1, 2024
Primary completion
Mar 2031 (estimated)
Completion
Mar 2031 (estimated)
Last update
Nov 25, 2025

Study contacts

Elizabeth Esterl, DNP, MS, RN
Contact
eesterl@allosource.org
7207326231
Paige McHenry, MS, ATC, CCRA
Contact
pmchenry@allosource.org
2154997062

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion